SGLT2-Is and MRAs combo associated with lower albuminuria in patients with type 2 DM
Combination therapy with SGLT2-Is and MRAs is associated with lower albuminuria in patients with type 2 DM compared to monotherapy with SGLT2-Is or MRAs alone suggests a new study published in Diabetes, Obesity and Metabolism
Diabetes mellitus (DM) is the leading cause of chronic kidney disease. Albuminuria is associated with an increased risk of cardiovascular mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) and mineralocorticoid receptor antagonists (MRAs) protect against albuminuria; however, their combined effects on albuminuria are unclear. We performed a network meta-analysis to investigate the effects of SGLT2-Is, MRAs, and their combination on albuminuria in type 2 DM.
Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K. (2023), Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes Obes Metab. Accepted Author Manuscript. https://doi.org/10.1111/dom.14976
Diabetes, Obesity and Metabolism, Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K, Effects, sodium-glucose, cotransporter 2 inhibitors, mineralocorticoid, receptor antagonists, combination, albuminuria, diabetic patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.